Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Corlopam
2. Fenoldopam
3. Fenoldopam Hydrobromide
4. Hydrobromide, Fenoldopam
5. Sk And F 82526
6. Sk And F 82526j
7. Sk And F-82526
8. Sk And F-82526j
9. Sk And F82526
10. Sk And F82526j
11. Skf 82526
12. Skf 82526j
13. Skf-82526
14. Skf-82526j
15. Skf82526
16. Skf82526j
1. 67227-57-0
2. Corlopam
3. Fenoldopam Methanesulfonate
4. Fenoldopam (mesylate)
5. Fenoldopam Mesilate
6. Corlopam Mesylate
7. Sk&f 82526-j
8. Fendolopam Mesylate
9. Nsc-759860
10. 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;methanesulfonic Acid
11. Ha3r0my016
12. Sk&f-82526j
13. 6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1h-3-benzazepine-7,8-diol Methanesulfonate (salt)
14. Fenoldopam Methanesulfonate;skf-82526 Mesylate
15. 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol,methanesulfonic Acid
16. 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, Methanesulfonate (salt)
17. Mls001401388
18. 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol Methanesulfonate
19. Einecs 266-612-7
20. Fenoldopam Mesylate [usan]
21. 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; Methanesulfonic Acid
22. Fenoldopam Monomethanesulfonate
23. Sk-82526-j
24. Skf 82526-j
25. Smr000469190
26. Unii-ha3r0my016
27. Skf 82526 (mesylate)
28. Fenoldopam Mesylate [usan:usp]
29. Corlopam (tn)
30. Skf-82526 Mesylate
31. Fenoldopam Mesylate (usp)
32. Chembl1026
33. Schembl41213
34. 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-(p-hydroxyphenyl)-1h-3-benzazepinium Methanesulphonate
35. 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol; Methanesulfonic Acid
36. Chebi:5003
37. Hy-b0735a
38. Dtxsid00904650
39. Hms2051p09
40. Hms2230j03
41. Hms3264b10
42. Hms3371l12
43. Hms3393p09
44. Hms3885l10
45. Pharmakon1600-01505539
46. Fenoldopam Mesylate [vandf]
47. Fenoldopam Mesilate [mart.]
48. Fenoldopam Mesilate [who-dd]
49. Fenoldopam Mesylate [usp-rs]
50. Nsc759860
51. S4618
52. Sk&f-82526-j
53. Akos030254549
54. Fenoldopam Mesylate, >=98% (hplc)
55. Ccg-100942
56. Ccg-213480
57. M27f569
58. Nc00192
59. Nsc 759860
60. Fenoldopam Methanesulfonate [mi]
61. Fenoldopam Mesylate [orange Book]
62. Ac-32753
63. As-57125
64. Fenoldopam Mesylate [usp Monograph]
65. Db-054999
66. Ft-0626401
67. C76117
68. D00613
69. A835665
70. W-104725
71. Q27279818
72. Z2210694608
73. Fenoldopam Mesylate, United States Pharmacopeia (usp) Reference Standard
74. 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1h-3-benzazepine-7,8-diol Mesylate
75. 1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, Methanesulphonate (salt)
76. 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;methanesulfonic Acid
77. 6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1h-3-benzazepine-7,8-diol Methanesulphonate (salt)
78. 6-chloro-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Methane Sulfonate
Molecular Weight | 401.9 g/mol |
---|---|
Molecular Formula | C17H20ClNO6S |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 1 |
Exact Mass | 401.0699862 g/mol |
Monoisotopic Mass | 401.0699862 g/mol |
Topological Polar Surface Area | 136 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 441 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Corlopam |
PubMed Health | Fenoldopam (Injection) |
Drug Classes | Antihypertensive |
Drug Label | Corlopam (Fenoldopam Mesylate Injection, USP) is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-... |
Active Ingredient | Fenoldopam mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Hospira |
2 of 4 | |
---|---|
Drug Name | Fenoldopam mesylate |
Drug Label | Fenoldopam Mesylate Injection, USP is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-7,8-diol me... |
Active Ingredient | Fenoldopam mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Eurohlth Intl; Sandoz |
3 of 4 | |
---|---|
Drug Name | Corlopam |
PubMed Health | Fenoldopam (Injection) |
Drug Classes | Antihypertensive |
Drug Label | Corlopam (Fenoldopam Mesylate Injection, USP) is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-... |
Active Ingredient | Fenoldopam mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Hospira |
4 of 4 | |
---|---|
Drug Name | Fenoldopam mesylate |
Drug Label | Fenoldopam Mesylate Injection, USP is a dopamine D1-like receptor agonist. The product is formulated as a solution to be diluted for intravenous infusion. Chemically it is 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[1H]-3-benzazepine-7,8-diol me... |
Active Ingredient | Fenoldopam mesylate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml |
Market Status | Prescription |
Company | Eurohlth Intl; Sandoz |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Dopamine Agonists
Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Fenoldopam (mesylate) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fenoldopam (mesylate), including repackagers and relabelers. The FDA regulates Fenoldopam (mesylate) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fenoldopam (mesylate) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Fenoldopam (mesylate) supplier is an individual or a company that provides Fenoldopam (mesylate) active pharmaceutical ingredient (API) or Fenoldopam (mesylate) finished formulations upon request. The Fenoldopam (mesylate) suppliers may include Fenoldopam (mesylate) API manufacturers, exporters, distributors and traders.
click here to find a list of Fenoldopam (mesylate) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fenoldopam (mesylate) DMF (Drug Master File) is a document detailing the whole manufacturing process of Fenoldopam (mesylate) active pharmaceutical ingredient (API) in detail. Different forms of Fenoldopam (mesylate) DMFs exist exist since differing nations have different regulations, such as Fenoldopam (mesylate) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fenoldopam (mesylate) DMF submitted to regulatory agencies in the US is known as a USDMF. Fenoldopam (mesylate) USDMF includes data on Fenoldopam (mesylate)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fenoldopam (mesylate) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fenoldopam (mesylate) suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fenoldopam (mesylate) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fenoldopam (mesylate) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fenoldopam (mesylate) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fenoldopam (mesylate) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fenoldopam (mesylate) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fenoldopam (mesylate) suppliers with NDC on PharmaCompass.
Fenoldopam (mesylate) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fenoldopam (mesylate) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fenoldopam (mesylate) GMP manufacturer or Fenoldopam (mesylate) GMP API supplier for your needs.
A Fenoldopam (mesylate) CoA (Certificate of Analysis) is a formal document that attests to Fenoldopam (mesylate)'s compliance with Fenoldopam (mesylate) specifications and serves as a tool for batch-level quality control.
Fenoldopam (mesylate) CoA mostly includes findings from lab analyses of a specific batch. For each Fenoldopam (mesylate) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fenoldopam (mesylate) may be tested according to a variety of international standards, such as European Pharmacopoeia (Fenoldopam (mesylate) EP), Fenoldopam (mesylate) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fenoldopam (mesylate) USP).
LOOKING FOR A SUPPLIER?